Lucid Diagnostics Q2 Earnings Call Highlights

Key Points

• Q2 revenue rose 17% sequentially to $1.5 million on 2,770 EsoGuard tests, although revenue recognition remained limited by reimbursement uncertainty and collection probability.
• Lucid secured its first laboratory benefit manager coverage policy through Concert, adopted by three health plans representing nearly 10 million covered lives, while it continues to await a Medicare draft LCD.
• The company ended June with $33.4 million in cash and quarterly cash burn of $11.3 million; management is prioritizing VA contracts, commercial coverage and health-system programs to increase revenue and reduce burn.

Lucid Diagnostics NASDAQ: LUCD reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while awaiting a Medicare draft local coverage determination, or LCD.

Chief Executive Officer Dr. Lishan Aklog said revenue increased about 17% from the prior quarter despite test volume remaining within the company’s established range. He attributed the revenue improvement to a greater commercial focus on testing opportunities more likely to generate payment.

The company said it is awaiting publication of a Medicare draft LCD and remains confident it will receive a positive draft policy. Aklog said there has been a broad backlog in LCD output at the Centers for Medicare & Medicaid Services, but noted that several long-awaited policies have been released in recent weeks.

Commercial Coverage Progress

During the quarter, Lucid secured its first laboratory benefit manager coverage policy for EsoGuard from Concert. According to Aklog, Concert concluded that EsoGuard is medically necessary for patients meeting established screening criteria and found the test’s evidence demonstrated improved health outcomes.

Concert’s policy has been adopted by three client health plans, while Lucid expects additional plans to adopt it in coming months. Aklog said Concert’s client plans collectively account for just under 10 million covered lives, although the company did not provide a specific estimate for how many lives are currently covered under adopted policies.

Laboratory benefit managers assess molecular diagnostic tests and develop coverage policies for health-plan clients. Aklog said the Concert decision could help Lucid’s discussions with other laboratory benefit managers and commercial payers, particularly because Concert evaluated other esophageal pre-cancer tests and deemed them investigational due to insufficient evidence.

Lucid is also developing a cost-effectiveness model with Dr. Nicholas Shaheen, lead author of American College of Gastroenterology guidelines, along with AGORA experts and international opinion leaders. The model is intended to measure the long-term clinical and economic effects of EsoGuard screening compared with current care, including Barrett’s esophagus detection, cancer stage shifting, cancer avoidance and cancer-related mortality.

Aklog said preliminary findings indicate EsoGuard appears cost-effective across nearly all modeled scenarios, though the company has not disclosed the underlying data. Lucid expects to complete the model during the summer and plans to submit the results for publication following peer review.

VA and Health-System Efforts

The company said its Veterans Affairs opportunity is progressing through clinical engagement, contracting and budget discussions. Aklog said the company has built a pipeline of VA centers and encountered little clinician resistance, but the VA did not contribute meaningfully to second-quarter test volume.

Lucid is seeking contracts for the federal fiscal year beginning Oct. 1. CFO Dennis McGrath said VA volume is expected to follow as the company obtains purchase orders and advances its pipeline.

Lucid also described ongoing work with health systems to build testing programs, including patient identification, ordering workflows, results management and electronic health record integration. Aklog said the company has begun final implementation work and active testing programs at multiple health systems.

The company has been shifting its commercial strategy away from heavier reliance on firefighter and healthcare-event testing toward primary-care, gastroenterology and health-system channels. McGrath said compensation plans are now more weighted toward Medicare, VA and contracted revenue opportunities. Just under 40% of second-quarter tests fit that category, he said, with government insurance accounting for about half of that portion and direct contracting accounting for the remainder.

Financial Position and Reimbursement

Lucid ended the quarter with $33.4 million in cash as of June 30, essentially unchanged from year-end. The company completed a common-stock offering during the quarter that generated approximately $16.8 million in net proceeds.

Average quarterly cash burn over the past four quarters, including cash interest on debt, was $11.6 million, while second-quarter burn was $11.3 million. Lucid’s non-GAAP operating expenses were $12.3 million, compared with an average of $12.2 million over the preceding five quarters.

The company has $22 million in secured convertible debt, structured as a five-year, interest-only note with a 12% interest rate and a $1 conversion price. McGrath said shares outstanding, including unvested restricted stock awards and previously converted preferred shares, were approximately 203 million. PAVmed remains Lucid’s largest common shareholder, with about 15% ownership.

Lucid said its 2,770 second-quarter tests represented more than $7.5 million in billable value, based on the company’s list price, but revenue recognition remains constrained by collection probability while reimbursement coverage is still developing. The company recognized about 19% of the quarter’s pro forma billable amount as revenue.

• About 65% of second-quarter claims had been adjudicated, while 35% remained pending.
• Of adjudicated claims, roughly 28% resulted in an allowable amount, averaging $1,424 per test.
• Common denial categories included determinations that testing was medically unnecessary or investigational, prior-authorization requirements, and requests for additional medical records.

McGrath said a positive Medicare policy would affect 40% to 50% of Lucid’s addressable patient population and would materially affect future revenue-recognition analysis. He also said tests performed for Medicare patients within 12 months before a final positive policy could be paid after the policy takes effect.

Management said it expects commercial spending and headcount to rise as reimbursement improves, but argued that the test’s pricing and incremental margin could limit the corresponding increase in cash burn. Aklog said the company’s most immediate opportunity to reduce burn is to increase revenue through VA contracts, contracted events and additional commercial coverage while it awaits Medicare action.

About Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company's flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid's CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source